Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spirit1 in ALS
NCT02588807Phase 1Withdrawn
- Sponsor
- Herb-Spirit
- Start
- Jan 2021
- Primary completion
- Sep 2021
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Spirit1 in amyotrophic lateral sclerosis (ALS), sponsored by Herb-Spirit. Primary endpoint: Tolerability and safety based on the number and severity of adverse events (AE) at 8 months. Planned start Jan 2021; status: withdrawn.
02
Drugs
Spirit1
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02588807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588807.